NXL Key Statistics, Chart & Performance
The current stock price of NXL is 0.62 USD. In the past month the price decreased by -17.33%. In the past year, price decreased by -83.33%.
NXL Technical Analysis
NXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NXL. NXL has a great financial health rating, but its profitability evaluates not so good.
NXL Financial Highlights
Over the last trailing twelve months NXL reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 0.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| Debt/Equity | 0 |
NXL Forecast & Estimates
5 analysts have analysed NXL and the average price target is 4.08 USD. This implies a price increase of 558.06% is expected in the next year compared to the current price of 0.62.
For the next year, analysts expect an EPS growth of 19.67% and a revenue growth 34.3% for NXL
NXL Ownership
NXL Latest News, Press Relases and Analysis
NXL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.02 | 188.146B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.95 | 169.625B | ||
| SYK | STRYKER CORP | 23.97 | 137.924B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.17 | 111.924B | ||
| BDX | BECTON DICKINSON AND CO | 13.75 | 59.33B | ||
| IDXX | IDEXX LABORATORIES INC | 43.44 | 51.339B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.38 | 46.291B | ||
| RMD | RESMED INC | 21.75 | 38.394B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.39 | 37.64B | ||
| DXCM | DEXCOM INC | 27.76 | 27.621B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NXL
Company Profile
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Company Info
NEXALIN TECHNOLOGY INC
1776 Yorktown, Suite 550
Houston TEXAS US
Employees: 6
Phone: 18322600222
NEXALIN TECHNOLOGY INC / NXL FAQ
Can you describe the business of NEXALIN TECHNOLOGY INC?
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Can you provide the latest stock price for NEXALIN TECHNOLOGY INC?
The current stock price of NXL is 0.62 USD. The price increased by 9.15% in the last trading session.
Does NEXALIN TECHNOLOGY INC pay dividends?
NXL does not pay a dividend.
How is the ChartMill rating for NEXALIN TECHNOLOGY INC?
NXL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is NEXALIN TECHNOLOGY INC (NXL) stock traded?
NXL stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for NEXALIN TECHNOLOGY INC?
The Revenue of NEXALIN TECHNOLOGY INC (NXL) is expected to grow by 34.3% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is NEXALIN TECHNOLOGY INC worth?
NEXALIN TECHNOLOGY INC (NXL) has a market capitalization of 11.56M USD. This makes NXL a Nano Cap stock.